Metrics

  • citations in SCIndeks: 0
  • citations in CrossRef:0
  • citations in Google Scholar:[]
  • visits in previous 30 days:8
  • full-text downloads in 30 days:5

Contents

article: 4 from 53  
Back back to result list
2021, vol. 37, iss. 84, pp. 2225-2225
Smoking and alcohol consumption as risk factors in 112 oncology patients diagnosed with bisphosphonate-associated osteonecrosis of the jaw
aMedicinski univerzitet Plovdiv, Fakultet za javno zdravlje, Departman za epidemiologiju i vanredne situacije u medicini, Plovdiv, Bugarska
bMedicinski univerzitet Plovdiv, Fakultet za javno zdravlje, Departman za socijalnu medicinu i javno zdravlje, Plovdiv, Bugarska
cUniverzitet u Plovdivu, Klinika za maksilofacijalnu hirurgiju, Univerzitetska bolnica "Sveti Georgije", Plovdiv, Bugarska
Project:
The paper was supported by the Ministry of Education and Science, Republic of Bulgaria (National program "Young scientists and postdoctoral students").

Abstract
Background: Bisphosphonate-associated osteonecrosis of the jaws (BAONJ) is a complication of great medical importance. Some of the most discussed and controversial aspects are the risk factors, some of which are related to patients' smoking and alcohol consumption. The Aim: To study cancer patients with BAONJ and determine their participation in the mentioned above risky health-related habits. Material and methods: A prospective epidemiological study of 112 patients diagnosed with bisphosphonate-associated osteonecrosis of the jaw in 2016 and 2017 was conducted at the Clinic of Maxillofacial surgery of University hospital "St. George", Plovdiv, Bulgaria, based on anamnesis, clinical examination, and hospital documentation. SPSS Statistics v.24 was used for statistical analysis, at a significance level p<0.05. Results: Over 2/3 of the patients were smokers (40.18%) or ex-smokers (25.00%), which linked them with the risk factor of smoking. At the time of the study, patients smoking between 1 and 9 and between 10 and 19 cigarettes a day had equal relative shares of 44.22%. More than half of the patients smoked from the age of 20-39, which we explain by the high average age. The majority of patients studied consumed alcohol, most often once a week or on weekends (28.57%) or only on occasions (26.79%), followed by 24.11% who used alcohol several times per week. Nearly 2/3 drink drinks with both low and high alcohol content. Conclusion: The highest proportion of patients are smokers / ex-smokers and consume alcoholic beverages occasionally, which links them to these risk potential factors.
References
*** (2010) Guideline: Prevention of osteonecrosis of the jaw (ONJ) in patients on bisphosphonate therapies. NWS health, https://www.aub.edu.lb/fm/CaMOP/Documents/G L2010_010.pdf (Accessed on September 28, 2020)
Almazrooa, S.A., Woo, S.B. (2009) Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: A review. Journal of the American Dental Association, 140(7): 864-875
Campisi, G., Fedele, S., Fusco, V., Pizzo, G., di Fede, O., Bedogni, A. (2014) Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Future Oncology, 10(2): 257-275
Ficarra, G., Beninati, F. (2007) Bisphosphonte-related osteonecrosis of the jaws: The point of view of the oral pathologist. Clin Cases Miner Bone Metab, 4: 53-7
Frazer-Cox, C. (2020) New MRONJ guidance. British Dental Journal, 229(3): 151-151
Izzotti, A., Menini, M., Pulliero, A., Dini, G., Cartiglia, C., Pera, P., Baldi, D. (2013) Biphosphonates-associated osteonecrosis of the jaw: The role of geneenvironment interaction. J Prev Med Hyg, 54(3): 138-183
Lee, L.W., Hsiao, S.H., Chen, L.K. (2014) Clinical treatment outcomes for 40 patients with bisphosphonates-related osteonecrosis of the jaws. Journal of the Formosan Medical Association, 113(3): 166-172
Lu, S.Y., Liang, C.C., Lin, L.H. (2014) Retrospective analysis of 27 cases of bisphosphonate-related osteonecrosis of the jaw treated surgically or nonsurgically. Journal of Dental Sciences, 9(2): 185-194
Marx, R.E. (2016) Risk factors for antiresorptive drugrelated osteonecrosis of the jaw. in: Fleisher Kenneth E.; Kontio Risto; Otto Sven [ed.] Antiresorptive Drug-related Osteonecrosis of the Jaw (ARONJ)-a Guide to Research, 39-44
Payne, K.F., Goodson, A.M., Tahim, A.S., Rafi, I., Brennan, P.A. (2017) Why worry about bisphosphonate-related osteonecrosis of the jaw?: A guide to diagnosis, initial management, and referral of patients. British Journal of General Practice, 67(660): 330-331
Pešić, Z., Zarev, M., Ranđelović, J. (2016) How much we know about bisphosphonate lesions. Acta stomatologica Naissi, vol. 32, br. 73, str. 1546-1554
Quispe, D., Shi, R., Burton, G. (2011) Osteonecrosis of the jaw in patients with metastatic breast cancer: Ethnic and socio-economic aspects. Breast Journal, 17(5): 510-513
Ruggiero, S.L., Dodson, T.B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., O'Ryan, F. (2014) American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update. Journal of Oral and Maxillofacial Surgery, 72(10): 1938-1956
Tenore, G., Palaia, G., Gaimari, G. (2014) Medication-related osteonecrosis of the jaws (MRONJ): Etiological update. Senses Sci, 1(4): 147-152
Thumbigere-Math, V., Tu, L., Huckabay, S., Dudek, A.Z., Lunos, S., Basi, D.L., Hughes, P.J., Leach, J.W., Swenson, K.K., Gopalakrishnan, R. (2012) A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. American Journal of Clinical Oncology, 35(4): 386-392
Wang, Q., Liu, J., Qi, S., Liao, X., Liu, D., Pan, J. (2018) Clinical analysis of medication related osteonecrosis of the jaws: A growing severe complication in China. Journal of Dental Sciences, 13(3): 190-197
Watters, A.L., Hansen, H.J., Williams, T., Chou, J.F., Riedel, E., Halpern, J., Tunick, S., Bohle, G., Huryn, J.M., Estilo, C.L. (2013) Intravenous bisphosphonate-related osteonecrosis of the jaw: Long-term follow-up of 109 patients. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 115(2): 192-200
Wei, L.Y., Kok, S.H., Lee, Y.C., Chiu, W., Wang, J., Cheng, S., Chang, H., Lee, J.C. (2021) Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid. Journal of the Formosan Medical Association, 120(8): 1572-1580
Wessel, J.H., Dodson, T.B., Zavras, A.I. (2008) Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: A case-control study. Journal of Oral and Maxillofacial Surgery, 66(4): 625-631
Woo, S.B., Hellstein, J.W., Kalmar, J.R. (2006) Systematic review: Bisphosphonates and osteonecrosis of the jaws. Annals of Internal Medicine, 144(10): 753-753
 

About

article language: Serbian, English
document type: Original Paper
DOI: 10.5937/asn2184225H
received: 07/05/2021
revised: 10/09/2021
accepted: 17/09/2021
published in SCIndeks: 26/01/2022
Creative Commons License 4.0

Related records